Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 2
1970 7
1971 1
1972 1
1973 1
1974 1
1976 3
1977 2
1978 2
1979 5
1980 7
1981 4
1982 12
1983 7
1984 11
1985 11
1986 8
1987 16
1988 8
1989 13
1990 19
1991 18
1992 11
1993 12
1994 17
1995 6
1996 8
1997 2
1998 5
1999 9
2000 9
2001 9
2002 12
2003 16
2004 12
2005 28
2006 18
2007 24
2008 30
2009 34
2010 32
2011 55
2012 47
2013 30
2014 43
2015 46
2016 40
2017 37
2018 48
2019 60
2020 59
2021 53
2022 39
2023 39
2024 16
2025 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

952 results

Results by year

Filters applied: . Clear all
Page 1
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. Among authors: foa r. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Foà R, et al. N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
How I treat adult Ph+ ALL.
Chiaretti S, Foà R. Chiaretti S, et al. Among authors: foa r. Blood. 2025 Jan 2;145(1):11-19. doi: 10.1182/blood.2023023152. Blood. 2025. PMID: 39172753 Review.
Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld A, Rousselot P, Ribera J, Bassan R. Gökbuget N, et al. Among authors: foa r. Blood. 2024 May 9;143(19):1903-1930. doi: 10.1182/blood.2023023568. Blood. 2024. PMID: 38306595 Free article.
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.
Bassan R, Chiaretti S, Della Starza I, Santoro A, Spinelli O, Tosi M, Elia L, Cardinali D, De Propris MS, Piccini M, Lussana F, Annunziata M, Chiusolo P, Zappasodi P, Borlenghi E, Leoncin M, Califano C, Bocchia M, Di Raimondo F, Grimaldi F, Tiribelli M, Candoni A, Lico A, Audisio E, Lunghi M, Mianulli AM, Di Trani M, Arena V, Messina M, Piciocchi A, Fazi P, Rambaldi A, Foà R. Bassan R, et al. Among authors: foa r. Blood. 2025 May 22;145(21):2447-2459. doi: 10.1182/blood.2024027500. Blood. 2025. PMID: 40009490 Clinical Trial.
952 results